(Q33845809)

29 July 2017

Topiramate antagonizes MK-801 in an animal model of schizophrenia (English)

1 reference

29 July 2017

0 references

5

John Mastropaolo

1 reference

29 July 2017

Stephen I Deutsch

1

1 reference

29 July 2017

Richard B Rosse

series ordinal

2

1 reference

29 July 2017

Eddie N Billingslea

series ordinal

3

1 reference

29 July 2017

Alan S Bellack

series ordinal

4

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 August 2002

1 reference

European Journal of Pharmacology

29 July 2017

1 reference

29 July 2017

449

1 reference

29 July 2017

1-2

1 reference

29 July 2017

121-125

1 reference

The glutamatergic dysfunction hypothesis for schizophrenia

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902041-1

Measurement of an explosive behavior in the mouse, induced by MK-801, a PCP analogue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902041-1

7-Nitroindazole and methylene blue, inhibitors of neuronal nitric oxide synthase and NO-stimulated guanylate cyclase, block MK-801-elicited behaviors in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902041-1

The competitive NMDA antagonist CPP blocks MK-801-elicited popping behavior in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902041-1

A revised excitotoxic hypothesis of schizophrenia: therapeutic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902041-1

Topiramate improves deficit symptoms in a patient with schizophrenia when added to a stable regimen of antipsychotic medication.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902041-1

Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902041-1

Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902041-1

The positive and negative syndrome scale (PANSS) for schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902041-1

The NMDA-receptor antagonist CPP abolishes neurogenic 'wind-up pain' after intrathecal administration in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902041-1

Computerized measurement of MK-801-elicited popping and hyperactivity in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902041-1

D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902041-1

Schizophrenia and glutamatergic transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902041-1

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0014-2999(02)02041-1

1 reference

29 July 2017

1 reference